BeiGene

Clinical Trials Appendix

Q1 2024 Results Update

May 8, 2024

Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding the projected dates for upcoming regulatory approvals and the estimated number of future approvals; and BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Our Pipeline Snapshot

Across three therapy areas:





130+

Clinical studies run by BeiGene

35+

New molecular entities (NME) in our development pipeline

24,000+

Patients enrolled in clinical trials globally*

70

Approvals for BRUKINSA (zanubrutinib) globally

* Includes investigator initiated trials (IITs)

BeiGene: Key upcoming regulatory action catalysts 2024 - 2025

Potential Approvals



1H, 2024

Q1

BRUKINSA – 212 R/R FL **US** ✓

TEVIMBRA – 302 2L ESCC **US** ✓

Q2

TEVIMBRA – 302 2L ESCC **Australia**

TEVIMBRA – 303/304/307 1L/2L NSCLC **EU** ✓

2H, 2024

Q3

TEVIMBRA – 302 2L ESCC **Brazil**

TEVIMBRA – 303 2L NSCLC **Brazil**

TEVIMBRA – 306 1L ESCC **US***

Q4

BRUKINSA – 302/304/305 WM and CLL/SLL **JP**

TEVIMBRA – 305 1L GC **US**

TEVIMBRA – 306 1L ESCC **Australia**

2025

BRUKINSA – additional ~20 global approvals

TEVIMBRA – 305 1L GC **EU**

TEVIMBRA – 306 1L ESCC **EU**

TEVIMBRA – 309 1L NPC **EU**

TEVIMBRA – 312 1L SCLC **EU**

TEVIMBRA – 302 2L ESCC **JP**

TEVIMBRA – 306 1L ESCC **JP**

TEVIMBRA – 305 1L GC **JP**

TEVIMBRA – additional ~15 global approvals

ESCC-Esophageal squamous cell carcinoma; R/R FL- Relapsed refractory follicular lymphoma; GC- Gastric cancer; NSCLC- Non-small cell lung cancer; Neo/adj NSCLC- neoadjuvant/adjuvant non-small cell lung cancer;
NPC- nasopharyngeal carcinoma; SCLC-Small cell lung cancer
*Due to a potential delay in scheduling clinical site inspections, the target PDUFA date of July 2024 may be deferred

BeiGene: Project movements in 2023 – 2024 to date

New to Phase 1

BGB-26808 (HPK1 2G)

BGB-30813 (DGKζ)

BGB-43395 (CDK4i)

BGB-A3055 (CCR8)

BGB-A317 tislelizumab (PD-1) SubQ

BGB-21447 (next gen BCL2i)

BG-68501 (CDK2i)

Xaluritamig* (STEAP1 x CD3) initiation activities

BG-C9074 (B7H4 ADC)

New to Phase II

BGB-16673 BTK CDAC R/R CLL, R/R MCL

1L NSCLC umbrella study

Neo/adj NSCLC umbrella study

BGB-A445 (OX40) Melanoma/RCC/UC novel combo umbrella

LBL-007 (LAG3) MSS CRC, 1L ESCC

New to pivotal trial

Tarlatamab* (DLL x CD3) 1L ES-SCLC initiation activities

Sonrotoclax TN CLL

New to registration

Tislelizumab 305 (1L GC) in US, EU

Tislelizumab 312 (1L ES-SCLC) in CN

Tislelizumab 306 (1L ESCC) in US, EU

Tislelizumab 315 (Neo/adj NSCLC) in CN

Approved

Zanubrutinib 212 (R/R FL) in US, EU

Tislelizumab 305 (1L GC) in CN, CN (FA)

Tislelizumab 306 (1L ESCC) in CN

Tislelizumab 302 (2L ESCC) in EU, US

Tislelizumab 301 (1L HCC) in CN

NSCLC- Non-small cell lung cancer; RCC- Renal cell carcinoma; UC-urothelial carcinoma; MSS CRC- microsatellite stable colorectal cancer; ESCC-Esophageal squamous cell carcinoma; ES-SCLC- extended stage small cell lung cancer; LS-SCLC- limited stage small cell lung cancer; TN CLL- treatment naïve chronic lymphocytic leukemia; GC- gastric cancer; Neo/adj NSCLC- neoadjuvant/adjuvant non-small cell lung cancer; R/R FL- relapsed refractory follicular lymphoma; HCC- hepatocellular carcinoma

*Amgen collaboration, BeiGene has China commercial rights and tiered mid-single digit royalties on net sales outside of China. "Initiation activities" refers to clinical activities, approval is obtained to initiate the study in China.

BeiGene: Project movements in 2023 – 2024 to date

Removed from Phase 1

BGB-B167 (CEAx4-1BB)

Removed from Phase II

Ociperlimab (TIGIT)
- 1L TNBC
- 1L HCC
- 2L ESCC
- 2L CC

Sitravatinib (RTKi)

Removed from Phase III

Sitravatinib (RTKi) 2L+ NSCLC

Ociperlimab (TIGIT) LA NSCLC

NSCLC- Non-small cell lung cancer; ESCC-Esophageal squamous cell carcinoma;
LA NSCLC- locally advanced non-small cell lung cancer; HCC- hepatocellular carcinoma; CC- cervical cancer, TNBC- triple negative breast cancer

CEAx4-1BB- Carcinoembryonic Antigen x 41BB; TIGIT- T cell immunoglobulin and ITIM domain; RTKI- receptor tyrosine kinase inhibitor

Innovative solid tumor NME early pipeline

Differentiated molecules with multiple modalities in priority tumor types

Lung

- PanKRASi
- MTA Cooperative PRMT5i
- EGFR CDAC
- CEA ADC
- B7H3 ADC
- EGFR x MET Tsp
- MUC1 x CD16A

Breast/Gynecological

- CDK4i*
- CDK2i*
- Next-gen BCL2i*
- B7H4 ADC*
- Claudin6 x CD3

GI



- PanKRASi
- FGFR2b ADC
- CEA ADC
- GPC3 x 4-1BB
- MUC1 x CD16A

Head & Neck



- SMAC Mimetics*
- MTA Cooperative PRMT5i
- B7H3 ADC

Pan Tumor

- DGKζi*
- HPK1i*
- CCR8*
- Pro-IL15

Small molecule | Protein degrader | Bi/Tri-specific
mAb | ADC | Cytokine therapy

BeiGene has global rights for CDK2 (Ensem partnership) and B7H4 ADC (DualityBio partnership)
* In the clinic

BeiGene: Building leadership in solid tumors with innovative NMEs

	Pre-Clinical	Phase 1	Phase 2	Phase 3
Breast/ Gynecological	**BGB-B455** **Claudin6xCD3** Gyn (other ST)	**BGB-43395 · CDK4** Breast (other ST) (Global and CN studies) **BGB-C9074** **B7H4-ADC** Breast (other ST) **BGB-10188** **PI3kδ** Ovarian Cancer **BG-68501** **CDK2i** Breast (other ST)		
Gastro-intestinal	**BG-C137** **FGFR2b ADC** GI **BG-C477** **CEA ADC** GI and Lung **BGB-B2033** **GPC3x4-1BB** Solid Tumors **BG-53038** **Pan-KRAS** GI and lung	**Zanidatamab** **HER2** 1L MBC/GC	**BGB-LBL-007** **LAG-3** MSS-CRC **BGB-LBL-007** **LAG-3** 1L ESCC **Zanidatamab** **HER2** 2L+ BTC	**Zanidatamab** **HER2** 1L HER2+ GEA
Lung	**BG-60366** **EGFR-CDAC 2G** Lung **BG-T187** **EGFRxMET** Lung and GI **BGB-B3227** **MUC1xCD16A** Lung and GI **BGB-58067** **MTA-coop PRMT5** Lung and HNSCC **BGB-C354** **B7H3 ADC** Lung and HNSCC	**Ociperlimab** **TIGIT** (Tisle combo dose finding)	**Umbrella** 1L NSCLC **Umbrella** 2L+ NSCLC **Umbrella** Neoadjuvant NSCLC **Tarlatamab** **DLL3xCD3** 3L+ SCLC (CN only)	**Ociperlimab** **TIGIT** 1L NSCLC (PDL1 high) **Tarlatamab** **DLL3xCD3** 2L SCLC (CN only) **Tarlatamab** **DLL3xCD3** LS-SCLC (CN only) **Tarlatamab** **DLL3xCD3** 1L ES-SCLC (CN only)
ST - Other	**BGB-R046** **Pro-IL15** Solid Tumors	**BGB-A3055** **CCR8** Solid Tumors **BGB-24714** **SMAC** Solid Tumors **BGB-26808** **HPK1 2G** Solid Tumors **BGB-15025** **HPK1** Solid Tumors **Xaluritamig** **STEAP1x CD3** mCRPC (CN only) **BGB-30813** **DGKζ** Solid Tumors	**BGB-A445** **OX40** Melanoma, RCC, UC **Surzebiclimab** **TIM-3** 1L HNSCC **Umbrella** 1L HNSCC	

NSCLC- Non-small cell lung cancer; RCC- Renal cell carcinoma; UC-urothelial carcinoma; MSS CRC- microsatellite stable colorectal cancer; GEA-Gastroesophageal adenocarcinoma; MBC-metastatic breast cancer; HNSCC-Head &Neck squamous cell carcinoma; mCRPC-metastatic castration-resistant prostate cancer; ES-SCLC-extended stage small cell lung cancer; LS-SCLC- limited stage small cell lung cancer; Neo/adj NSCLC- neoadjuvant/adjuvant non-small cell lung cancer;

BeiGene: Building leadership in solid tumors with LCM

	Phase 1	Phase 2	Phase 3	Approved
Breast/ Gynecological			**Pamiparib** **PARPi** 2L+ MTx OC	**Pamiparib · PARPi** 2L+ gBRCAm OC **Baituowei (Goserelin)** Breast, Prostate
Gastro-intestinal			**Tislelizumab** **PD-1** localized ESCC	**Tislelizumab** **PD-1** 1L HCC **Tislelizumab** **PD-1** 2L ESCC **Tislelizumab** **PD-1** 1L GC **Tislelizumab** **PD-1** 1L ESCC **Tislelizumab** **PD-1** 1L NPC **Tislelizumab** **PD-1** 2L/3L+HCC
Lung			**Tislelizumab** **PD-1** 1L ES-SCLC **Tislelizumab** **PD-1** neo/adj NSCLC	**Tislelizumab** **PD-1** 1L Non-sq. NSCLC **Tislelizumab** **PD-1** 1L Sq. NSCLC **Tislelizumab** **PD-1** 2/3L NSCLC
ST - Other	**Tislelizumab PD-1** Subcutaneous administration		**Tislelizumab** **PD-1** 1L UBC	**Tislelizumab** **PD-1** 2L UC **Tislelizumab** **PD-1** R/R cHL **Tislelizumab** **PD-1** MSI-H/dMMR ST

LCM – life cycle management, NSCLC- Non-small cell lung cancer; NSq-non squamous; Sq squamous; ES-SCLC-extended stage small cell lung cancer; LS-SCLC- limited stage small cell lung cancer; Neo/adj NSCLC- neoadjuvant/adjuvant non-small cell lung cancer; ESCC-Esophageal squamous cell carcinoma; UBC- urinary bladder cancer; OC ovarian cancer; HCC-hepatocellular carcinoma; NPC-nasopharyngeal carcinoma, GC-gastric cancer, MSI-H- microsatellite stability high; dMMR-mismatch repair deficient; R/R cHL- relapsed refractory classic Hodgkins lymphoma

BeiGene: A leader in hematology / I&I portfolio – innovative NMEs

	Pre-Clinical	Phase 1	Phase 2	Phase 3
AML/MDS		**Sonrotoclax** **BCL2i** AML/MDS		
cHL				
B-Cell		**BGB-21447** **BCL2i 2G** B-Cell Malignancies **Ociperlimab** **TIGIT** R/R DLBCL **Sonrotoclax** **BCL2i** B-Cell Malig.(China) **Sonrotoclax** **BCL2i** mono & combo w/ zanu (Global) **BGB-16673** **BTK CDAC** B-Cell Malig. (China) **BGB-16673** **BTK CDAC** B-Cell Malig. (Global)	**BGB-16673** **BTK CDAC** R/R MCL & R/R CLL **Sonrotoclax** **BCL2i** post BTKi R/R MCL **Sonrotoclax** **BCL2i** post BTKi CLL/SLL (China) **Sonrotoclax** **BCL2i** R/R WM	**Sonrotoclax** **BCL2i** TN CLL combo + zanu
MM		**Sonrotoclax** **BCL2i** Multiple Myeloma with t(11;14)		
Heme - Other				
I&I	**BGB-45035** **IRAK4 CDAC**			

ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; cHL=classic Hodgkin lymphoma; CLL=chronic lymphocytic leukemia; DLBCL=diffuse large B-cell lymphoma; FL=follicular lymphoma; MCL=mantle cell lymphoma; MDS=myelodysplastic syndromes; MM=multiple myeloma; WM=Waldenstrom macroglobulinemia; MZL=marginal zone lymphoma; SLL=small lymphocytic lymphoma

BeiGene: A leader in hematology / I&I with LCM

	Phase 1	Phase 2	Phase 3	Approved
AML/MDS				
cHL			**Tislelizumab** **PD-1** R/R cHL (China)	**Tislelizumab** **PD-1** R/R cHL
B-Cell	**Zanubrutinib** **BTKi** R/R DLBCL revlimib combo	**Zanubrutinib** **BTKi** Previous BTKi Tx ibru/acala intolerant **Zanubrutinib** **BTKi** R/R CLL/SLL (JP) **Zanubrutinib** **BTKi** R/R B-cell lymphoma **Zanubrutinib** **BTKi** CD98B R/R DLBCL	**Zanubrutinib** **BTKi** TN MCL **Zanubrutinib** **BTKi** R/R MZL, R/R FL	**Zanubrutinib** **BTKi** TN CLL/SLL **Zanubrutinib** **BTKi** R/R CLL/SLL **Zanubrutinib** **BTKi** R/R MCL **Zanubrutinib** **BTKi** R/R MZL **Zanubrutinib** **BTKi** R/R FL **Zanubrutinib** **BTKi** TN WM
MM				
Heme - Other		**BLINCYTO®** **CD3/CD19 BiTE** Pediatric RR BP-ALL		
I&I		**Zanubrutinib** **BTKi** Lupus Nephritis	**Zanubrutinib** **BTKi** PMN	

LCM – life cycle management, ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; cHL=classic Hodgkin lymphoma; CLL=chronic lymphocytic leukemia; DLBCL=diffuse large B-cell lymphoma; FL=follicular lymphoma; MCL=mantle cell lymphoma; MDS=myelodysplastic syndromes; MM=multiple myeloma; WM=Waldenstrom macroglobulinemia; MZL=marginal zone lymphoma; SLL=small lymphocytic lymphoma



Trial detail

- **BRUKINSA®** (zanubrutinib)
- **Sonrotoclax**
- **TEVIMBRA®** (tislelizumab)

BeiGene

BRUKINSA®
Foundational asset in hematology portfolio

Approved medicines
Late-stage development
Early development

Trial	Clinicaltrials.gov	Population	Total Patients	Combination molecule	Status
BGB-3111-111	NCT04172246	B-Cell Malignancies (JP only)	55		Active
BGB-3111-215	NCT04116437	Previous BTKi Tx - ibru/acala intolerant	97		Enrolling
BGB-3111-218	NCT05068440	CD79b R/R DLBCL	66		Enrolling
BGB-3111-306	NCT04002297	TN MCL	510	rituximab	Active
BGB-3111-308	NCT05100862	R/R MZL and FL	800	rituximab / obinutuzumab	Enrolling
BGB-3111-LTE1	NCT04170283	B-Cell Malig. Long Term Extension Study	1323		Enrolling
BGB-3111-206	NCT03206970	R/R MCL	86		Approved
BGB-3111-212	NCT03332017	R/R NHL - FL	217	obinutuzumab	Approved
BGB-3111-214	NCT03846427	R/R MZL	68		Approved
BGB-3111-302	NCT03053440	TN & R/R WM	229		Approved
BGB-3111-304	NCT03336333	TN CLL/SLL	784		Approved
BGB-3111-305	NCT03734016	R/R CLL/SLL	652		Approved

Brukinsa®
zanubrutinib

Sonrotoclax

Potential best-in-class BCL2 inhibitor with differentiated profile

Approved medicines
Late-stage development
Early development

Trial	Clinicaltrials.gov	Population	Total Patients	Combination molecule	Status
BGB-11417-101	NCT04277637	B-Cell Malignancies	438	zanubrutinib and obinutuzumab	Enrolling
BGB-11417-102	NCT04883957	B-Cell Malignancies	64		Active
BGB-11417-103	NCT04771130	AML/MDS	265	azacitidine	Enrolling
BGB-11417-105	NCT04973605	R/R MM with t(11;14)	181	dexamethasone and carfilzomib	Enrolling
BGB-11417-201	NCT05471843	Post-BTKi MCL	122		Enrolling
BGB-11417-202	NCT05479994	Post-BTKi CLL/SLL	97		Enrolling
BGB-11417-203	NCT05952037	R/R WM	85	zanubrutinib	Enrolling
BGB-11417-301	NCT06073821	TN CLL/SLL	640	zanubrutinib	Enrolling

TEVIMBRA®
Poised for Global Patient Impact

Approved medicines
Late-stage development
Early development

Trial	Clinicaltrials.gov	Population	Total Patients	Combination Molecule	Status
BGB-A317-103	NCT06091943	Subcutaneous administration	69		Enrolling
BGB-HNSCC-201	NCT05909904	1L HNSCC	160	LAG3, TIM-3, chemotherapy	Enrolling
BGB-LC-201	NCT05635708	1L NSCLC	319	LAG3, OX40, HPK, chemotherapy	Enrolling
BGB-LC-202	NCT05577702	1L Neo adj/adj NSCLC	120	LAG3, Chemotherapy	Enrolling
BGB-A317-310	NCT03967977	1L UBC	436	Chemotherapy	Enrolling
BGB-A317-311	NCT03957590	Localized ESCC	366	Chemotherapy+ radiotherapy	Active
BGB-A317-312	NCT04005716	1L ES-SCLC	455	Chemotherapy	Closeout
BGB-A317-315	NCT04379635	neo-adjuvant/adjuvant NSCLC	450	Chemotherapy	Filed
BGB-A317-203	NCT03209973	R/R cHL	68		Approved*
BGB-A317-204	NCT04004221	2L UC	110		Approved*
BGB-A317-208	NCT03419897	2L/3L+ HCC	250		Approved*
BGB-A317-209	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150		Approved*
BGB-A317-301	NCT03412773	1L HCC	680		Approved*
BGB-A317-302	NCT03430843	2L ESCC	489		Approved
BGB-A317-303	NCT03358875	2/3L NSCLC	805		Approved
BGB-A317-304	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	Approved
BGB-A317-305	NCT03777657	1L GC	978	Chemotherapy	Approved*
BGB-A317-306	NCT03783442	1L ESCC	650	Chemotherapy	Approved*
BGB-A317-307	NCT03594747	1L Sq. NSCLC	342	Chemotherapy	Approved
BGB-A317-309	NCT03924986	1L NPC	263	Chemotherapy	Approved*

TEVIMBRA (tislelizumab)

* Approved in China

BeiGene